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Abstract
Senescence, a persistent form of cell cycle arrest, is often associated with a diverse secretome, 
which provides complex functionality for senescent cells within the tissue microenvironment. We 
show that oncogene-induced senescence (OIS) is accompanied by a dynamic fluctuation of 
NOTCH1 activity, which drives a TGF-β-rich secretome, whilst suppressing the senescence-
associated pro-inflammatory secretome through inhibition of C/EBPβ. NOTCH1 and NOTCH1-
driven TGF-β contribute to ‘lateral induction of senescence’ through a juxtacrine NOTCH-JAG1 
pathway. In addition, NOTCH1 inhibition during senescence facilitates upregulation of pro-
inflammatory cytokines, promoting lymphocyte recruitment and senescence surveillance in vivo. 
Because enforced activation of NOTCH1 signalling confers a near mutually exclusive secretory 
profile compared to typical senescence, our data collectively indicate that the dynamic alteration of 
Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, 
subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
*Correspondence: masashi.narita@cruk.cam.ac.uk. 
Author Contributions
MH and MN designed the experiments; MH, YI and AJP carried out the in vitro experiments; MPW, NJM and RA performed and 
analysed the proteomics experiments; MH and TWK performed and analysed the in vivo experiments; DAP and SS performed the 
HSEC experiments; SM and RS performed bioinformatic analysis; KT provided reagents; WH performed the analysis of 
immunohistochemistry images. PJL, LZ and MN provided resources; MH and MN wrote the manuscript; all authors reviewed and 
edited the manuscript.
Europe PMC Funders Group
Author Manuscript
Nat Cell Biol. Author manuscript; available in PMC 2017 March 01.
Published in final edited form as:
Nat Cell Biol. 2016 September ; 18(9): 979–992. doi:10.1038/ncb3397.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
NOTCH1 activity during senescence dictates a functional balance between these two distinct 
secretomes: one representing TGF-β and the other pro-inflammatory cytokines, highlighting that 
NOTCH1 is a temporospatial controller of secretome composition.
Introduction
Cellular senescence is an autonomous tumour suppressor mechanism, whereby various 
triggers drive a stable proliferative arrest. Senescence is accompanied by diverse 
biochemical changes including upregulation of CDK inhibitors, the accumulation of 
senescence-associated β-galactosidase (SA-β-gal) activity, and expression of a wide variety 
of secretory proteins1,2. These features of senescence have been recapitulated by in vivo 
models, including both pathological and physiological contexts3.
Senescent cells have profound non-autonomous functionality in the tissue microenvironment 
through the senescence-associated secretory phenotype (SASP)2. Previous studies have 
demonstrated heterogeneous effects of the SASP upon tumorigenesis. The SASP can 
reinforce the senescent phenotype in both an autocrine and paracrine fashion4–6 and activate 
immune clearance of senescent cells7–9 from tissues, thereby contributing to tumour 
suppression. Some tumorigenic activities of SASP have also been shown through promoting 
cellular growth and epithelial–mesenchymal transition in neighbouring immortalised or 
transformed epithelial cells10,11. In addition, SASP components, among others, include 
inflammatory cytokines and matrix-modifying enzymes, which play key roles in the 
clearance of senescent or damaged cells and resolution of tissue injury, respectively. Thus, it 
is conceivable that both the relative and absolute expression of SASP components is 
dynamic and under tight regulation. However, the basis for the regulation of different SASP 
components or controlling the net function of the SASP is unclear.
NOTCH signalling is evolutionarily conserved and involved in a wide range of 
developmental and physiological processes, controlling cell-fate specification and stem cell 
homeostasis12 In addition, alterations of the NOTCH pathway have been linked to stress 
response and tumorigenesis, where it can be oncogenic or tumour suppressive depending on 
tissue and context13. There are four NOTCH receptors, which bind the Jagged (JAG) and 
Delta-like family of ligands12. Upon ligand binding the NOTCH receptors undergo a series 
of proteolytic cleavage events liberating the intracellular domain (ICD), which subsequently 
translocates to the nucleus to bind a multi-molecular complex, including both the DNA-
binding protein, RBP-J and Mastermind-like (MAML) co-activators12 and drive 
transcription of NOTCH-target genes, such as the HES/HEY family of transcription factors 
(TFs). Importantly, NOTCH ligands are also transmembrane proteins; thus, signalling is 
thought to be restricted to adjacent cells through juxtacrine interaction, and the role of 
NOTCH in autocrine or paracrine signalling through secreted factors remains unclear.
Through a quantitative cell surface proteome of oncogene-induced senescent (OIS) cells and 
subsequent validation, we have identified a global upregulation of NOTCH1 that is 
accompanied by dynamic alteration of its downstream activity during senescence. We 
describe how NOTCH1 functions as a master regulator of SASP composition through a 
temporal and functional switch between two distinct secretomes, representing TGF-β or pro-
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inflammatory cytokines, in part through downregulation of C/EBPβ. We show that inhibiting 
Notch signalling promotes clearance of OIS cells in the liver, implying a unique therapeutic 
opportunity to target senescent cells through modulation of immune surveillance.
Results
Plasma membrane proteome in OIS
To gain a better understanding of the phenotype of OIS cells, particularly potential mediators 
of non-cell-autonomous signalling, we conducted a proteomic screen of plasma membrane 
(PM) surface proteins utilising a quantitative SILAC approach14 in IMR90 human diploid 
fibroblasts (HDFs) expressing oncogenic HRASG12V in a 4-hydroxytamoxifen (4OHT)-
inducible form (ER:HRASG12V) (Fig. 1a, Supplementary Fig. 1A)15. We identified peptides 
from 1502 independent proteins with. enrichment for localisation in PM or extracellular 
compartments in Gene Ontology (GO) analysis (Fig. 1b). Of the 1502 proteins, 521 were 
identified with ‘high confidence’ (see METHODS) with 32 and 135 significantly up and 
downregulated respectively in HRASG12V-induced senescent (RIS) cells (Fig. 1c, 
Supplementary Table 1).
To validate our proteomic findings, we compared the RIS-associated PM changes with 
transcriptomic data and identified a significant positive correlation between mRNA and 
protein changes during RIS (Supplementary Fig. 1B).
NOTCH1 is upregulated in OIS
To understand signalling networks involving senescence-associated PM proteins we 
conducted network enrichment analysis, utilising both transcriptomic and proteomic data. 
The highest enriched network contained the NOTCH1 receptor as a major network hub and 
its canonical targets (HES1, HEY1, and HEYL) and binding partners (RBPJ and MAML3) 
(Fig. 1c, Supplementary Fig. 1C).
Utilising flow cytometry we confirmed the substantial upregulation of cell surface NOTCH1 
during senescence induced by different triggers (oncogenic MEK or DNA damage) or RIS in 
different HDFs (Fig. 1d, Supplementary Fig. 1D, E). In contrast, bypass of RIS through co-
expression of the adenoviral oncoprotein, E1A failed to up-regulate cell surface NOTCH1 on 
IMR90 cells (Fig. 1d). Although the NOTCH pathway has recently been implicated in 
senescence16–18, its functional relevance is unclear.
NOTCH1 signalling is dynamically regulated during senescence
We next investigated the temporal changes of cell surface NOTCH1 and its downstream 
activity after ER:HRASG12V induction. In this system, senescence develops progressively 
from an initial mitotic phase (~d1) to senescence establishment (~d6) (Supplementary Fig. 
1A)15. After a slight reduction at the mitotic phase, cell surface NOTCH1 continually 
increased during RIS (Fig. 2a). However, the cleaved, active NOTCH1 intracellular domain 
(N1ICD) and the canonical NOTCH1-target HES1 were transiently upregulated during the 
transition to senescence, but returned to near basal level at full senescence (Fig. 2b). The 
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transient activation of NOTCH1 signalling, despite increased cell surface NOTCH1, was 
also observed during DNA damage-induced senescence (DDIS) (Fig. 2c, Fig. 1d right)19.
Characterised SASP components include multiple pro-inflammatory cytokines, such as IL-1, 
IL-6 and IL-86,11,20,21. More recently, TGF-β ligands have been identified as SASP 
components, which are involved in senescence induction, in part through inducing p15 and 
p214,5. IL-6 and IL-8 were primarily upregulated at full senescence. However, we found a 
transient induction of TGF-β ligands during both RIS and DDIS, reminiscent of the N1ICD 
expression pattern (Fig. 2b, c, Supplementary Fig. 2A), suggesting that NOTCH signalling 
temporally correlates with the reciprocal induction of TGF-β and pro-inflammatory 
cytokines during senescence.
NOTCH1 reciprocally regulates TGF-β and pro-inflammatory cytokines
To examine the relationship between NOTCH1 and regulation of secretory factors during 
RIS, we first introduced a dominant negative form of MAML1, fused to mVenus 
(dnMAML1-mVenus), into ER:RASG12V-expressing IMR90 cells. At d3 after ER:RASG12V 
induction, expression of dnMAML1 led to minimal effect upon proliferation, but completely 
blocked the induction of HES1 (Fig. 2d). This inhibition of NOTCH signalling significantly 
reduced the upregulation of TGFB1, suggesting that NOTCH is upstream of HRASG12V-
driven TGF-β induction (Fig. 2d). Conversely, upregulation of pro-inflammatory cytokines 
(IL-8, IL1A, and IL1B) was enhanced by dnMAML1, suggesting that activated NOTCH1, 
during senescence transition, negatively regulates the expression of pro-inflammatory 
cytokines. Similar results were obtained pharmacologically with DAPT, a gamma secretase 
inhibitor, which blocks cleavage and release of the N1ICD (Supplementary Fig. 2B). 
Notably, the endogenous levels of N1ICD were modestly increased in the presence of 
dnMAML1 regardless of HRASG12V-induction (Figure 2d). This is consistent with previous 
studies showing that N1ICD levels are controlled by negative feedback through MAML-
dependent proteasomal degradation, providing a potential mechanism for the decoupling of 
surface NOTCH1 and N1ICD levels 22.
We next introduced a doxycycline-inducible N1ICD-FLAG system into IMR90 cells 
(Supplementary Fig. 2C). Restoration of N1ICD at the late phase of RIS (d6) led to a dose-
dependent decrease in IL1A, IL1B and IL-8 expression and a dose-dependent increase in 
TGFB1 expression, with minimal impact on senescence arrest (Fig. 2e). Therefore, during 
RIS, the dynamic alteration of NOTCH1 controls the temporally reciprocal pattern of TGF-
β1 and pro-inflammatory cytokines and manipulating NOTCH signalling allows for SASP 
modulation with senescence arrest being maintained.
Enforced activation of NOTCH1 induces a unique senescence phenotype in HDFs
Consistent with recent reports16–18, expression of ectopic N1ICD drove a senescence-like 
morphological change with stable cell cycle arrest, although accumulation of SA-β-gal 
activity was relatively modest (Fig. 3a, b, Supplementary Fig. 2D, E). Note, proliferative 
arrest was maintained even after removal of ectopic N1ICD, the hallmark of senescence 
(Supplementary Fig. 2E). Overexpression of N1ICD was sufficient for reduction of basal 
IL-8 levels as well as induction of TGF-β1 and its downstream effector phosphorylated 
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SMAD3 (Fig. 3a, c, d). Thus, ectopic N1ICD induces senescence that is distinct from RIS or 
DDIS, particularly in its SASP composition.
To understand the broader implications of NOTCH1 in the control of secretome 
composition, we performed mRNA-seq analysis of senescent IMR90 cells driven by 
HRASG12V, DNA damage, or N1ICD. Transcriptional profiling of secretory factors of RIS 
and DDIS shared large clusters (Fig. 3e). Gene Set Enrichment Analysis (GSEA) showed 
that all types of senescence shared a common cell-cycle signature (Supplementary Fig. 3A). 
However, the secretome expression profile of N1ICD-induced senescence (NIS) exhibited an 
almost mutually exclusive pattern with RIS and DDIS, particularly in those shared clusters 
(Fig. 3e). Many secretory factors that have been associated with RIS or DDIS, such as pro-
inflammatory cytokines and matrix metalloproteinases (MMP1/3/10), were repressed by 
ectopic N1ICD. Downregulated secretory factors at d6 of RIS, including TGF-β ligands 
(TGFB1/2/3) were upregulated by ectopic N1ICD in IMR90 cells. GSEA revealed a close 
association of TGF-β1 signatures with NIS (Supplementary Fig. 3B). To understand the 
relative dominance of RAS and N1ICD upon the secretome composition we analysed 
secretome transcriptional data from IMR90 cells undergoing RIS, NIS or expressing both 
RAS and N1ICD (N+RIS). Unsupervised clustering revealed the similarity between NIS and 
N+RIS secretomes, where ectopic N1ICD mostly overcame the RIS pattern (Supplementary 
Fig. 3C). Interestingly, such dominance of NOTCH over RAS also applied to GLB1, 
encoding the lysosomal enzyme responsible for SA-β-Gal activity23, potentially explaining 
the modest SA-β-Gal activity of NIS (Fig. 3b). Altogether, our data suggest that NIS and 
RIS are associated with reciprocal secretory profiles, and that dynamic NOTCH1 activity 
during senescence determines the balance between two extremities: one representing TGF-β 
ligands and the other representing ‘classical’ SASP components including pro-inflammatory 
cytokines.
NOTCH1-driven cell-autonomous senescence is partly dependent on TGF-β signalling
To understand how N1ICD induces senescence, we expressed N1ICD in the presence or 
absence of inhibitors of the TGF-β receptor (TGFBR1). Inhibition of TGF-β signalling 
prevented upregulation of TGF-β targets, p15 and TGFB-induced (TGFBI), in N1ICD-
expressing cells, and partly rescued the anti-proliferative effect of N1ICD (Fig. 3f, 
Supplementary Fig. 4A, left). Similar results were also obtained by expression of a dominant 
negative form of SMAD4 (dnSMAD4) (Supplementary Fig. 4B, left)24. Importantly, 
recombinant TGF-βs alone had no anti-proliferative effect on IMR90 cells (Supplementary 
Fig. 4C and D), suggesting that NOTCH-driven TGF-β signalling contributes to senescence 
cooperatively with other NOTCH1-downstream factor(s), as yet to be elucidated.
Non-cell-autonomous effects of NOTCH1 on normal cells
To investigate the non-cell-autonomous effects of differing forms of senescence, we set up 
co-culture experiments of mRFP-labelled, otherwise normal, IMR90 cells with senescent 
IMR90 cells induced by N1ICD, HRASG12V or DNA damage. To avoid confounding effects 
of the ‘TGF-β phase’ of SASP during RIS and DDIS, senescence was pre-induced for 4 
days before co-culture. We found that mRFP-labelled cells co-cultured with NIS, but not late 
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phase RIS or DDIS cells, at least in IMR90 cells, underwent a growth arrest, suggesting a 
key role for the NOTCH1-driven secretome in the transmission of senescence (Fig. 4a).
To understand signalling pathways that might underpin N1ICD-mediated non-autonomous 
growth arrest, we co-cultured NIS and mRFP-IMR90 cells for 72 hours prior to flow sorting 
and then analysing gene expression in both cell populations. Consistent with N1ICD-
mediated induction of TGF-β ligands in the mono-culture experiments (Fig. 3c-e), both 
N1ICD-expressing and mRFP-cells exhibited upregulation of the TGF-β targets, p15/
CDKN2B and TGFBI (Fig. 4b). Similarly to autonomous NOTCH1 activation, TGFBR1 
inhibitors or dnSMAD4 partially rescued the non-autonomous growth arrest in mRFP-cells 
when co-cultured with N1ICD-expressing cells (Fig. 4c, Supplementary Fig. 4A, B).
To further examine whether N1ICD-expressing cells induce senescence in neighbouring 
cells, we took advantage of the difference in the drug selection markers of retroviral vectors 
expressing either N1ICD (or control vector) or mRFP: after co-culturing N1ICD-expressing 
cells (hygromycin resistant) and mRFP-expressing cells (puromycin resistant), cells were 
incubated with puromycin for 2 days to remove N1ICD-expressing cells (Fig. 4d). After 
additional culture for 5 days, mRFP cells that had been co-cultured with N1ICD-expressing 
cells, but not with vector-expressing cells, exhibited a senescent phenotype (Fig. 4d, e). 
Importantly, this phenotype was maintained even after the removal of the signal-sending 
cells, indicating that the N1ICD-expressing cells transmitted a senescent phenotype to the 
neighbouring cells.
N1ICD-induced ‘lateral induction’ of senescence
The role of NOTCH in biological patterning during development is attributed to processes 
termed ‘lateral inhibition’ and ‘lateral induction’25: NOTCH-mediated downregulation of 
NOTCH ligands in the same cells will negatively regulate NOTCH signalling in 
neighbouring cells (lateral inhibition), whereas NOTCH-mediated upregulation of NOTCH 
ligands will positively regulate NOTCH activity in neighbouring cells (lateral induction)26.
Interestingly, activation of downstream NOTCH signalling was observed not only in the 
N1ICD-expressing cells, but also in the co-cultured target cells with increased expression of 
HES1 (Fig. 4b). In addition, basal levels of IL1A were repressed in both cell populations 
(Fig. 4b), suggesting that NOTCH signalling was transmitted from N1ICD-expressing cells 
to neighbouring cells. Among the five canonical NOTCH ligands12, we found a strong, 
unique upregulation of JAG1 upon ectopic N1ICD expression (Fig. 5a, Supplementary Fig. 
5A). Although shedding of extracellular domain of JAG1 has been reported, we did not 
detect this in conditioned media (CM) from NIS cells (Supplementary Fig. 5B)27. Induction 
of JAG1 was also observed during the transition to RIS with up and subsequent down-
regulation mirroring the dynamic expression of N1ICD (Supplementary Fig. 2A). Induction 
of senescence with increased JAG1 was confirmed in N1ICD-expressing hTERT-RPE1 cells 
(Supplementary Fig. 5C). These results suggest that N1ICD activation induces a cell-contact 
dependent growth arrest through a process similar to embryonic lateral induction. To further 
corroborate this, we examined how downstream inhibition of NOTCH signalling in the 
mRFP-expressing target cells affected non-cell-autonomous suppression of proliferation in 
the co-culture system. Consistent with our hypothesis, use of DAPT led to a dose-dependent 
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inhibition of the non-cell-autonomous growth arrest of mRFP-expressing cells co-cultured 
with N1ICD-expressing cells (Fig. 5b, Supplementary Fig. 5D). As expected, it had no effect 
upon autonomous cell growth in cells expressing N1ICD, which acts downstream of gamma 
secretase activity (Fig. 5c). More specifically, dnMAML1-mediated inhibition of NOTCH 
signalling only in the mRFP-expressing target cells also led to resistance to the non-cell-
autonomous growth arrest in the co-culture system (Fig. 5d).
We next inhibited NOTCH ligand activity in N1ICD-expressing cells. RNAi-mediated 
knockdown of JAG1 in the N1ICD-expressing IMR90 cells had no effect upon cell 
autonomous growth of these cells (Fig. 5e, f), but led to a dose-dependent inhibition of the 
non-cell-autonomous growth arrest in the co-cultured mRFP-expressing cells (Fig. 5g, 
Supplementary Fig. 5D). Culturing the N1ICD- and mRFP-expressing cells apart using a 
transwell chamber led to only a marginal decrease in proliferation of the mRFP-labelled 
cells (Fig. 5h), supporting the critical role for cell-cell contact in activation of NOTCH 
signalling and subsequent senescence induction in cells adjacent to N1ICD-expressing cells. 
Similar NOTCH-mediated senescence transmission was also observed in mRFP-expressing 
IMR90 cells co-cultured with N1ICD-expressing RPE1 cells, where JAG1 was upregulated 
(Supplementary Fig. 5C, E). Although it is known that TGF-β signalling can induce JAG1 
expression28, neither TGFBR1 inhibitors or expression of dnSMAD4 affected the N1ICD-
mediated upregulation of JAG1 in HDFs (Fig. 5i), reinforcing that NOTCH is an upstream 
regulator of TGF-β. Together, these data indicate that N1ICD-expression leads to cell-
autonomous upregulation of both JAG1 and TGF-β ligands; the former triggers lateral 
induction of NOTCH signalling, and together with TGF-β signalling, induces senescence in 
neighbouring cells (Supplementary Fig. 5F). Interestingly, the NOTCH-mediated 
transmission of senescence was blocked by co-existing RIS cells, which were expressing 
dnMAML1 to minimise the inhibitory effect of NOTCH on the ‘RIS-secretome’, 
highlighting the functional distinction between non-autonomous activities of the two phases 
of RIS. This might also be involved in the negative feedback of NOTCH activity observed in 
the late phase of RIS in culture (Supplementary Fig. 5G).
NOTCH1 activation during OIS in vivo
To test whether Notch signalling is involved in senescence in vivo, we first examined 
KrasG12D-driven pancreatic intraepithelial neoplasia (PanIN) in KrasLSL-G12D; p48-cre mice, 
previously demonstrated to show evidence of senescence29. It was shown that Hes1 is 
upregulated in KrasG12D-driven mouse PanIN30–32. While most cells in adult wild-type 
pancreas exhibited low levels of Notch1 (Supplementary Fig. 6A), Notch1 was highly 
upregulated in PanIN cells that were positive for the senescence marker, Dec129, although 
the nuclear staining of Notch1 appeared heterogeneous (Supplementary Fig. 6A). Notch1 
was also upregulated in acinar to ductal metaplasia, a potential histological precursor for 
PanIN, previously linked to senescence33 (Supplementary Fig. 6A).
Non-cell-autonomous effects of NOTCH1 on immune clearance of senescent cells
We also examined the level of Notch1 in a mouse liver OIS model, in which transposable 
elements containing oncogenic NRASG12V are stably transduced to hepatocytes through the 
hydrodynamic tail-vein injection (HDTV): it was shown that NRASG12V-driven senescent 
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hepatocytes are often surrounded by immune cells, and progressively cleared by a CD4+ T-
cell-dependent immune reaction8. We found that cellular levels of Notch1 were upregulated 
in hepatocytes expressing NRASG12V, but not in hepatocytes expressing the non-functional 
NRASG12V/D38A (Fig. 6a).
To test whether Notch inhibition during NRASG12V-driven hepatocyte senescence would 
modulate immune-mediated clearance of these cells, we compared two cohorts of mice, 
injected with NRASG12V or NRASG12V combined with dnMAML1. Consistent with 
previous reports8, we observed a time-dependent clearance of NRASG12V-induced senescent 
hepatocytes (Fig. 6b, c). In the presence of Notch inhibition, this clearance was accelerated 
with a reduction in NRASG12V- and p21-expressing hepatocytes at d12 post-HDTV (Fig. 6b, 
c). Strikingly, in NRASG12V-expressing hepatocytes, the frequency of nuclear Hes1 positive 
cells progressively increased over time (Fig. 6d, Supplementary Fig. 6B), while, at d12 when 
most NRASG12V-expressing hepatocytes had been eliminated, the frequency was more 
variable between mice. Thus, the dynamic regulation of Notch activity observed in vitro 
OIS/DDIS (Fig. 2b, c) was recapitulated in vivo. Moreover, NRAS-expressing hepatocytes 
were often associated with neighbouring Hes1- or p21-expressing hepatocytes that did not 
express NRAS, at least at d9 (Fig. 6d, Supplementary Fig. 6C, D), providing in vivo 
evidence for senescence-associated lateral induction of Notch signalling. Note, we failed to 
observe any inhibition of NRASG12V-driven senescence (probed by p21) by dnMAML1, 
particularly up to d9, in both NRAS-positive and negative hepatocytes (Fig. 6c, 
Supplementary Fig. 6E): we speculate that dnMAML1 is likely to inhibit juxtacrine-
mediated, but not paracrine-mediated4–6 or cell-autonomous, senescence. These data 
reinforce the immune-modulating function of Notch expression.
We confirmed the recruitment of immune cells into the liver injected with NRASG12V; 
recruitment of CD3+ T-lymphocytes, but not B220+ B-lymphocytes, was significantly 
accelerated in NRASG12V-IRES-dnMAML1 injected livers compared to NRASG12V-IRES-
mVenus injected animals (Fig. 6c, Supplementary Fig. 6F and G).
Leucocyte recruitment to the liver requires a leucocyte adhesion cascade to sinusoidal 
endothelial cells, which separate the liver parenchyma from sinusoidal blood flow34. To 
examine the effect of NOTCH1-modulated secretomes upon lymphocyte recruitment, we 
performed an in vitro flow adhesion assay35: Human sinusoidal endothelial cells (HSECs), 
derived from explanted livers, were incubated in differentially conditioned media (CM) from 
IMR90 cells, prior to analysis of the ability of peripheral blood lymphocytes (PBLs) from 
healthy volunteers to adhere to HSECs under conditions of shear stress, recapitulating the 
physiological context of liver sinusoids (Supplementary Fig. 7A, B). CM from late phase 
(d6) of RIS IMR90 cells led to a significant increase in PBL adherence to HSECs and this 
effect was abrogated by co-expression of N1ICD (Fig. 6e). Similarly, inhibition of the 
NOTCH-regulated secretome at RIS transition (d3) led to significant increases in PBL 
adherence to HSEC when compared to HRASG12V-conditioned medium (Fig. 6e). 
Therefore, RIS-driven secreted factor(s) act upon HSECs to facilitate lymphocyte adhesion, 
which is negatively regulated by NOTCH through modulation of the SASP.
Hoare et al. Page 8
Nat Cell Biol. Author manuscript; available in PMC 2017 March 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
We next injected NRASG12V or NRASG12V-IRES-N1ICD into mice; surprisingly, the 
number of NRAS-positive hepatocytes was much lower in the presence of ectopic N1ICD 
even at d6 (Fig. 7a). To understand potential reasons for this, we stained the livers for 
cleaved Caspase 3 (CC3), an apoptosis marker, and found hepatocytes expressing 
NRASG12V-IRES-N1ICD were often CC3-positive (Fig. 7b, c). Nevertheless, in longer-term 
cohorts, most NRASG12V-IRES-N1ICD-, but no NRASG12V-,injected mice developed liver 
tumours (Fig. 7d, e, f). Thus, despite the efficient induction of apoptosis, ectopic NRASG12V 
and N1ICD cooperate to drive tumorigenesis. It remains to be elucidated whether this 
tumour formation is due to escape from senescence arrest and/or senescence surveillance, 
but the results underscore the context-dependent interaction between RAS and NOTCH 
signalling during tumorigenesis.
Our data collectively suggest that, at the endogenous level, Notch signalling modulates 
SASP composition in senescent hepatocytes, controlling the immune reaction in the liver 
and thereby negatively regulating the elimination of senescent hepatocytes, at least in part 
through suppressing T-lymphocyte recruitment to the liver.
NOTCH1 regulates senescence secretome through repression of C/EBPβ
To examine how NOTCH1 controls secretome composition, we measured the impact of 
N1ICD on two TFs: NFκB and C/EBPβ, previously shown to cooperatively regulate the 
SASP6,21,36. NFκB activation is primarily regulated through nuclear translocation, and 
consistent with previous studies20,36, the level of chromatin-bound RELA/p65, the major 
component of NFκB, was increased in RIS cells with its level in whole cell lysates being 
unchanged (Fig. 8a). In distinction, C/EBPβ was upregulated in both whole cell and 
chromatin fractions during RIS (Fig. 8a)6,21,36. Strikingly, ectopic N1ICD expression 
diminished levels of C/EBPβ, but not RELA, in both whole and chromatin fractions in RIS 
cells (Fig. 8a, compare lanes 2 and 4), although ectopic N1ICD appeared to be sufficient to 
inhibit the basal level of chromatin-bound RELA (Fig. 8a, compare lanes 1 and 3, 
Supplementary Fig. 8A).
In addition, N1ICD-mediated repression of C/EBPβ was abrogated in the presence of 
dnMAML1 (Fig. 8b). GSEA revealed enrichment of a C/EBPβ-signature37 in NIS or N
+RIS-downregulated genes, and RIS-upregulated genes (Supplementary Fig. 8B), suggesting 
that the transcriptional activity of C/EBPβ is broadly diminished in N1ICD-expressing 
IMR90 cells.
CEBPB translates from different in-frame start sites generating two transcriptional 
activators, LAP* and LAP (Liver-activating protein), and an N-terminally truncated 
transcriptional inhibitor, LIP (Liver inhibitory protein)6. We introduced full length CEBPB 
cDNA (LAP*, see METHODS) 6, to inducible N1ICD-expressing IMR90 cells. The 
enforced expression of LAP* in N1ICD-expressing cells fully restored expression of IL-8 
(Fig. 8c, compare lanes 2 and 4) and IL1A (Fig. 8d), suggesting that repression of pro-
inflammatory cytokines by N1ICD is primarily mediated by inhibition of C/EBPβ, although 
we do not exclude a role for N1ICD in qualitative regulation of the NFκB pathway.
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The preferential downregulation of C/EBPβ was also observed when IMR90 cells were 
treated with recombinant TNF-α. Ectopic N1ICD, which inhibited TNF-α-mediated pro-
inflammatory cytokine induction, had no effect on the level of TNF-α-activated RELA (Fig. 
8e) or other NFκB family components (Supplementary Fig. 8C), whereas N1ICD efficiently 
downregulated C/EBPβ in both basal and TNF-α-treated conditions. Further, ectopic 
N1ICD-driven downregulation of C/EBPβ was also observed in the HaCaT cells, where 
N1ICD failed to induce senescence, suggesting that NOTCH1-mediated C/EBPβ inhibition 
is not limited to senescence (Supplementary Fig. 8D).
It is well established that IL-1α acutely activates NFκB and C/EBPβ to induce their targets, 
including IL1B, IL6, and IL838. In the context of senescence, it was shown that IL-1α is an 
upstream SASP effector, regulating a cytokine network through NFκB and C/EBPβ21. Thus, 
it is possible that N1ICD negatively regulates IL-1α and thereby C/EBPβ. However, 
overexpression of C/EBPβ was sufficient for inducing IL1A even in the presence of ectopic 
N1ICD (Fig. 8d). In addition, when we treated N1ICD-expressing cells with recombinant 
IL-1α, we observed only a modest increase of C/EBPβlevels, whereas IL-6 was strongly 
upregulated to a level higher than control cells (Fig. 8f), suggesting that IL-1α, like IL-1β/
6/8, is also downstream of C/EBPβ.
Unlike IL1B/6/8, the transcriptional regulation of IL1A is unclear. To test whether C/EBPβ 
directly regulates IL1A expression during senescence, we first characterised the basal profile 
of C/EBPβ binding sites along with key epigenetic marks in IMR90 cells using external 
datasets39,40. We found several C/EBPβ peaks around the IL1A locus, including a modest 
‘proximal’ C/EBPβ peak at the transcriptional start site (TSS) and a prominent ‘distal’ site 
~8kb upstream of the TSS (Supplementary Fig. 8E). The proximal and distal sites were 
enriched for promoter and enhancer markers, respectively (Supplementary Fig. 8E). 
Interestingly, these two sites were recently identified as a promoter-enhancer pair, forming a 
looping interaction41, suggesting that this distal site is an enhancer for IL1A. Next, we 
performed C/EBPβ ChIP-qPCR, targeting these two regulatory regions of IL1A, as well as 
known C/EBPβ binding sites at the IL6/8 loci in IMR90 cells expressing N1ICD, 
HRASG12V, or both. Consistent with previous reports6, C/EBPβ promoter binding at the 
IL6/8 loci was increased in RIS cells (Supplementary Fig. 8F). Similarly, we found that C/
EBPβ binding at promoter and, more prominently, enhancer regions of IL1A was also 
increased (Fig. 8g), reinforcing that IL1A is a direct C/EBPβ target. In addition, co-
expression of N1ICD resulted in reduced enrichment of C/EBPβ at these regulatory regions 
in the context of HRASG12V (Fig. 8g). We propose that NOTCH1 inhibits pro-inflammatory 
cytokines, including IL-1α, primarily through repression of their C/EBPβ-mediated 
transcription (Fig. 8h).
Discussion
The data that we present here suggests that the SASP is not a singular entity, but a complex 
evolving entity with tightly regulated composition and spatial activity, dependent upon levels 
of NOTCH activity. We provide evidence for an additional layer of non-autonomous activity 
of senescence: ‘lateral induction’, which was originally described in NOTCH-mediated 
control of boundary formation during embryonic development25. Interestingly, recent 
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studies have identified embryonic senescence as a mechanism for developmental patterning: 
these senescent cells are accompanied by upregulation of TGF-β signalling and subsequent 
immune-clearance 42,43.
Another TF involved in embryonic development, GATA4, positively regulates the SASP in 
part through upregulation of IL-1α44 and NOTCH signalling appears to have a negative 
impact on GATA4 45. It would also be interesting to test whether GATA4 plays a role in 
NOTCH-mediated inhibition of the C/EBPβ-IL1a axis. Additional implications of our data 
include a possibility that constitutively active NOTCH signalling in tumour cells drive lateral 
induction of senescence in the stroma. Emerging evidence suggests the important role of 
bone marrow stroma in survival/maintenance of T-cell ALL, which is associated with 
activating mutations of NOTCH146. It would be important to test whether NOTCH 
signalling derived from T-ALL cells can induce NIS-like phenotype in the bone marrow 
stromal cells, which might have a substantial impact on the T-ALL niche.
Finally, therapeutic elimination of senescent cells has been suggested to provide beneficial 
effects on tissue homeostasis or tumour suppression7,8,47,48. Manipulation of NOTCH may 
provide a unique therapeutic opportunity for targeting senescent cells through modulation of 
senescence surveillance.
Methods
Cell culture
IMR90 (ATCC), WI38 (ATCC) and ESFs (embryonic skin fibroblasts)49 (a kind gift from 
Dr. Jesus Gil, Imperial College, London) human diploid fibroblasts were cultured as 
previously described in DMEM /10% fetal calf serum (FCS) in a 5% O2 / 5% CO2 
atmosphere. hTERT-RPE1 cells (a telomerase-immortalised human retinal pigment 
epithelial cell line) (ATCC) were grown in DMEM/F12 / 10% FCS in a 5% O2 / 5% CO2 
atmosphere. HACAT, cells (ATCC) were cultured in DMEM / 10% FCS in a 21% O2 / 5% 
CO2 atmosphere. No cell lines used in this study were found in the database of commonly 
misidentified cell lines that is maintained by ICLAC and NCBI Biosample. Cell identity was 
confirmed through STR genotyping. Regular testing was always negative for mycoplasma 
contamination.
The following drugs and inhibitors were used: 4-hydroxytamoxifen (4OHT) (Sigma); N-
[(3,5-Difluorophenyl)acetyl]-L-alanyl-2-phenyl]glycine-1,1-dimethylethyl ester (DAPT) 
(Sigma); SB431542 (Tocris); A 83-01 (Tocris); GW788388 (Tocris); Etoposide (Sigma); 
recombinant human TGF-β1 (Cell Signaling); recombinant human TGF-β2 (Peprotech); 
recombinant human TGF-β3 (Peprotech); Tumor necrosis factor alpha (TNF-α); 
recombinant IL-1α (both R&D systems).
Vectors
The following retroviral vectors were used in this study: pBabe-puro for HRASG12V50, C/
EBPβ-LAP* (alternative start codons were replaced with TTG; a kind gift from Dr. Daniel 
Peeper, NKI, Amsterdam)6; pLNCX2 (Clontech) for ER:HRASG12V15; pLNCX (Clontech) 
for ΔMEK1:ER (ΔN3, S218E, S222D)51; pWZL-hygro for N1ICD-FLAG (residues 1758 – 
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2556 of human NOTCH1, as described52), mRFP1; pLPC-puro for dnMAML1-mVenus 
(residues 12 – 74 of human MAML1), N1ICD-FLAG, mRFP1; pQCXIH-i N1ICD-FLAG, 
N1ICD-FLAG-mVenus, C/EBPβ-LAP*, dnSMAD4-mVenus (residues 1 - 514 of human 
SMAD4, as described 24); pQCXIN-i for N1ICD-FLAG; pMSCV-miR30-puro for shJAG1 
(target sequences: #1, 5’-GCGTGACCTGTGATGACTACT-3’; and #4, 5’-
GGTCTTTGAGCTCCCACTTCT-3’).
The tetracycline-inducible retroviral vectors (pQCXIH-i and pQCXIN-i) were cloned using 
the following strategies. A third generation tet-responsible element (TRE3G) and a 
constitutively expressed rtTA3 tet-transactivator cassette were PCR-amplified from pCLIIP-
i19. These two fragments were assembled by overlap-extension PCR and the product was 
cloned into pQCXIH or pQCXIN (Clontech).
Plasmids for Hydrodynamic tail-vein injection: pPGK-SB13, pT/CAGGS for NRASG12V, 
NRASG12V/D38A8, NRASG12V-IRES-mVenus, NRASG12V-IRES-dnMAML1-mVenus, 
NRASG12V-IRES-N1ICD-FLAG).
SILAC labelling
Cells were cultured in SILAC DMEM (Thermo) supplemented with 10% dialysed FCS (Life 
Technologies), L-proline (280mg/l, Sigma), L-glutamine (Life technologies) and either light 
(Arg 0, Lys 0) (Sigma), medium (Arg 6, Lys 4) or heavy (Arg 10 Lys 8) amino acids 
(CKGas) at 150mg/l and 85mg/l for lysine and arginine respectively. Cells were cultured for 
9 days to allow complete labelling of the proteome with the appropriate amino acids before 
induction of senescence.
Plasma membrane proteomics
PMP was performed as described previously14. Briefly, surface sialic acid residues were 
oxidised, biotinylated with aminooxy-biotin (Biotium), and biotinylated cells incubated in a 
1% Triton X-100 lysis buffer. Biotinylated glycoproteins were enriched with high affinity 
streptavidin agarose beads (Pierce) and washed extensively. Captured protein was reduced 
and alkylated then digested with trypsin on-bead overnight. Tryptic peptides were collected 
and fractionated. Glycopeptides were eluted using PNGase (New England Biolabs).
High pH reverse-phase high pressure liquid chromatography (HpRP-HPLC) was performed 
on tryptic peptides as described previously14. LC-MSMS was performed using a 
NanoAcquity uPLC (Waters, MA, USA) coupled to an LTQ-OrbiTrap XL (Thermo, FL, 
UA). Raw MS files were processed using MaxQuant version 1.3.0.553. Reversed decoy 
databases were used and the false discovery rate for both peptides and proteins were set at 
0.01. Protein quantitation utilised razor and unique peptides and required a minimum of 2 
ratio counts, with normalised protein ratios reported. Significance B values were calculated. 
We assessed the number of PM proteins identified as described previously14.
Proteomic Analysis
Proteins were selected for differential expression analysis such that they had been quantified 
in at least two replicates, and that at least one of these quantifications was based on more 
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than one peptide. A single sample t-test was then applied to the mean log2 fold change 
values to assess whether these were significantly different to zero. Proteins were selected as 
significantly differentially expressed if p value <0.05. All detected proteins were used for 
enrichment testing of GO localisation (Cellular Component) terms using Metacore 
(Thomson Reuters). ’High confidence’ was defined as follows: peptides identified in at least 
2 independent replicates with at least 1 replicate having 2 or more peptides.
Expression profiling by mRNA sequencing
RNA was extracted using the Qiagen RNeasy plus kit according to manufacturer’s 
instructions and RNA quality checked using a Bioanalyser Eukaryote Total RNA Nano 
Series II chip (Agilent). mRNASeq libraries were prepared from at least 6 biological 
replicates of each condition using the TruSeq Stranded mRNA Library Prep Kit (Illumina) 
according to the manufacturers instructions. Single-end 40bp reads generated on the 
Illumina HiSeq were aligned to the human genome version GRCh37.64 using TopHat 
v2.0.454. Read counts were then obtained using HTSeq-count v0.5.3p9 (http://www-
huber.embl.de/users/anders/HTSeq/doc/overview.html), normalised and tested for 
differential gene expression using the Bioconductor package DESeq v1.10.155. Multiple 
testing correction was applied using the Benjamini-Hochberg method. Genes were selected 
as differentially expressed with a false discovery rate (FDR) of <0.01. Secretome genes were 
defined as previously described56.
Network analysis of proteomic and transcriptomic data
RIS-associated PMP data complemented by mRNA-Seq expression data were used to 
identify key senescence-associated membrane protein network hubs. Proteins detected 
through PMP were merged with genes, but genes annotated in the cellular membrane 
compartment were excluded. Log2 fold ratios were used for both proteomics and 
transcriptomic data. Data were analysed using Ingenuity Pathway Analysis (IPA) 
(QIAGEN); the possible interaction networks were generated using Ingenuity knowledge 
base and included only direct relationships. Default settings were used, apart from restricting 
the networks to experimentally observed interactions in human data. The highest scoring 
network as assigned by IPA, presented here, highlighted the importance of NOTCH1 as a 
key hub in the PMP data. For graph readability we removed interactions from non-hub 
genes.
Chromatin isolation
Chromatin isolation was performed as described previously50.
BrdU incorporation, colony formation and SA-β-gal assays
Cellular proliferation by BrdU incorporation, colony formation and SA-β-gal analysis have 
been described previously50.
Cellular proliferation by Incucyte
Analysis of short-term cellular proliferation was performed in either an Incucyte-HD or 
Incucyte-Zoom device (Essen Bioscience) in a 21% O2 atmosphere. Cells were plated, at 4 x 
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105 cells for monoculture or at 3.5 x 105 signal-sending cells with 1.5 x 105 target cells, in a 
12-well plate in 1ml cell culture media. Cell proliferation was determined through repeated 
measures of confluency on phase or epifluorescent imaging.
Gene set enrichment analyses (GSEA)
GSEA were performed as described57. P-values derived from DESeq analyses of the RNA-
Seq data were –log10 transformed and then signed according to whether any particular 
genes was up(+)- or down(-)-regulated compared to control samples. These values were then 
used for ranking and weighting of genes in subsequent GSEA analyses58. Cell-cycle related 
genesets were obtained from the Molecular Signatures Database (http://
software.broadinstitute.org/gsea/msigdb). Other gene signatures used were obtained from 
datasets in the Gene Expression Omnibus (GEO).
Flow cytometry
Cells were washed once with cold PBS, prior to dissociation with Versene (Life 
Technologies), washed twice more in PBS / 0.1% Fetal calf serum, blocked in 1% mouse or 
rabbit serum before incubation with combinations of the following fluorochrome-conjugated 
antibodies: anti-NOTCH1 (Ebioscience, 17-9889, 1:50); anti-JAGGED1 (R&D systems, 
FAB1726A, 1:8); anti-latency associated peptide (Ebioscience, 17-9829, 1:20). Cells were 
then washed twice more, before fixation with 4% PFA and analysis on a FACSCalibur 
(Becton Dickenson). Flow-based cell sorting was conducted on a FACSAria II cytometer 
(Becton Dickenson). Flow data was analysed with FlowJo v10.
Laser Scanning Cytometry
Cell cycle profile analysis was performed using Laser Scanning Cytometry on an iCys 
Research Imaging Cytometer (CompuCyte, Cambridge, MA) using anti-BrdU (BD, 555627, 
1:500) and counter-staining with DAPI.
mRNA expression by quantitative RT-PCR
RNA was extracted using the Qiagen RNeasy plus kit as above and reverse transcribed to 
cDNA using the high capacity reverse transcription kit (Applied Biosystems). qRT-PCR was 
performed as described before50 with relative expression determined by the 2-ΔΔCt 
method59 using β-Actin (ACTB) as an internal control. Primer sequences are as follows:
ACTB forward primer GGACTTCGAGCAAGAGATGG
ACTB reverse primer AGGAAGGAAGGCTGGAAGAG
CCNA2 forward primer GCGTTCACCATTCATGTGGA
CCNA2 reverse primer CAGGGCATCTTCACGCTCTATT
CDKN2B forward primer GCGTTCACTCCAATGTCTGCTG
CDKN2B reverse primer TCCACTTTGTCCTCAGTCTTCAGG
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CEBPB forward primer CTTCAGCCCGTACCTGGAG
CEBPB reverse primer GGAGAGGAAGTCGTGGTGC
JAG1 forward primer TGGTCAACGGCGAGTCCTTTAC
JAG1 reverse primer GCAGTCATTGGTATTCTGAGCACAG
TGFBI forward primer CCACCATCACCAACAACATCCAG
TGFBI reverse primer GCCGTTACCTTCAAGCATCGTG
IL1A forward primer AACCAGTGCTGCTGAAGGA
IL1A reverse primer TTCTTAGTGCCGTGAGTTTCC
IL1B forward primer CTGTCCTGCGTGTTGAAAGA
IL1B reverse primer TTGGGTAATTTTTGGGATCTACA
IL6 forward primer TGAAAGCAGCAAAGAGGCACTG
IL6 reverse primer TGAATCCAGATTGGAAGCATCC
IL8 forward primer AAGGAAAACTGGGTGCAGAG
IL8 reverse primer: ATTGCATCTGGCAACCCTAC
TGFB1 forward primer CAGAAATACAGCAACAATTCC
TGFB1 reverse primer CTGAAGCAATAGTTGGTGTC
TGFB3 forward primer TGCGTGAGTGGCTGTTGAGAAG
TGFB3 reverse primer CCATTGGGCTGAAAGGTGTGAC
HES1 forward primer ACGTGCGAGGGCGTTAATAC
HES1 reverse primer ATTGATCTGGGTCATGCAGTTG
HEY1 forward primer CCGCTGATAGGTTAGGTCTCATTTG
HEY1 reverse primer TCTTTGTGTTGCTGGGGCTG
Protein expression by immunoblotting and Immunofluorescence
Immunofluorescence and immunoblotting, on SDS-PAGE on gels of various concentrations, 
were performed as described previously50. The following antibodies were used in this study: 
anti-HRAS (Calbiochem, OP-23, 1:500); Anti-Cyclin A2 (Sigma, C4710, 1:500); anti-
NOTCH1 (Cell signaling, 4380, 1:1000); anti-N1ICD (Cell signaling, 4147, 1:500); anti-
HES1 (Cell signaling, 11988, 1:1000); anti-TGF-β1 (Cell signaling, 3709, 1:500); anti-IL-6 
(R&D systems, MAB2061, 1:250); anti-IL-8 (R&D systems, MAB208, 1:500); anti-β-Actin 
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(Sigma, A5441, 1:5000); anti-GFP (Clontech, 632377, 1:1000); anti-Rb (Cell signaling, 
9309, 1:1000); anti-JAGGED1 (Cell signaling, 2155, 1:1000); anti-FLAG (Cell signaling, 
2368, 1:1000); anti-C/EBPβ-LAP (Cell signaling, 3087, 1:1000); anti-C/EBPβ (Santa-Cruz, 
sc-150, 1:500); anti-Histone H3 (Abcam, Ab-1791, 1:10,000); anti-RelA (Cell signaling, 
3034, 1:1000); anti-RelB (Cell signaling, 4922, 1:1000); anti-c-Rel (Cell signaling, 4727, 
1:1000); anti-NF-kB1 (Cell signaling, 3035, 1:1000); anti-NF-kB2 (Cell signaling, 4882, 
1:1000); anti-IkBα (Cell signaling, 4814, 1:1000); anti-phospho-IkBα (Cell signaling, 
9246, 1:1000); anti-p16 (Santa-Cruz, sc-759, 1:500); anti-p21 (Santa-Cruz, sc-397, 1:1000); 
anti-SMAD2/3 (Cell signaling, 8685, 1:1000); anti-phospho-SMAD3 (Abcam, ab52903, 
1:1000); anti-TGFB-induced (Cell signalling, 5601, 1:1000). Full scans of all 
immunoblotting is included in supplementary figure 9, including molecular weight markers.
Protein from conditioned media was obtained by plating 2.5 x 106 cells in media with 2% 
FCS for 16 hours before filtration through a 0.22 μm filter and then centrifugation at 4000g 
for 20minutes through a Vivaspin 6 concentrator column (10kDa molecular weight cut-off, 
GE healthcare). Coomassie staining of gels was performed as previously reported50.
Hydrodynamic tail-vein injection
All animal experiments were approved by the German or UK legal authorities, and mice 
were kept under pathogen-free conditions in accordance with the institutional guidelines of 
the University of Tuebingen or University of Cambridge.
Male and female C57BL/6 mice were purchased from Charles River and injected at 5 – 8 
weeks of age. Vectors for hydrodynamic injection were prepared with the Qiagen EndoFree 
MaxiPrep kit. Transposon-mediated gene transfer was previously described8; briefly 20μg of 
appropriate vector and 5μg of SB13 transposase-containing plasmid were diluted in sterile-
filtered phosphate-buffered saline to a total volume of 10% of the body weight of the animal 
before being injected into the lateral tail vein in under 10 seconds.
Immunohistochemistry
Formalin fixed paraffin-embedded mouse tissues were stained with the following antibodies: 
anti-Notch1 (Cell signaling, 3608, 1:200); anti-Dec1 (a kind gift from Prof. Adrian Harris, 
1:2000); anti-NRAS (Santa Cruz, sc-31, 1:100); anti-Hes1 (Cell signaling, 11988, 1:250); 
anti-p21 (BD, 556431); anti-CD3 (Dako, A0452, 1:1000); anti-B220 (R&D systems, 
MAB1217, 1:1500); anti-ki67 (Bethyl, IHC-00375, 1:1000); anti cleaved caspase 3 (Cell 
signaling, 9664, 1:1000) after heat-induced epitope retrieval in citrate (pH6) or Tris-EDTA 
(pH9) buffers before visualisation using the DAKO Envision kit according to manufacturers 
instructions and counterstaining with haematoxylin. Dual chromogenic IHC staining was 
performed on a Leica Bond Max (Leica) using the polymer refine detection and refine red 
detection kits (Leica). For fluorescent labelling, we utilised anti-CD3 (as above) and anti-
GFP (Abcam, ab13970, 1:100) with appropriate fluorochrome-tagged secondary antibodies 
(Life Technologies).
All slides were scanned on a Leica AT2 at 20x magnification and a resolution of 0.5μm/
pixel. Following digitisation, image analysis was performed using the HALO (Indicalabs), 
utilising the Cytonuclear v1.4 algorithm. Each stain was trained independently to provide the 
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best accuracy for cell counting and all the slides were reviewed manually following analysis 
to assess accuracy. NRAS staining was counted manually from 4 random high power fields 
containing a median of 1457 hepatocytes (range 1304 – 1678) as described previously 8, due 
to problems segmenting individual cells when staining was very intense.
Isolation and culture of human liver sinusoidal endothelial cells (HSEC)
Tissue samples and blood samples from patients were obtained with written informed 
consent and with local ethics committee approval (LREC reference 06/Q2702/61, 
Birmingham, UK and 04/Q2708/41, Birmingham, UK). Liver endothelial cells were isolated 
from explanted livers or donor tissue surplus to surgical requirements using a collagenase 
digestion (collagenase type 1a, Sigma-Aldrich) as described previously60. All tissue was 
collected from patients in the Liver Unit at Queen Elizabeth Hospital in Birmingham with 
informed consent and under local ethics committee approval. Briefly, digested tissue was 
placed over a 33% / 77% Percoll (Amersham Biosciences) density gradient. The endothelial 
cells were isolated by immunomagnetic selection using Abs against CD31 conjugated to 
Dynabeads (Life Technologies). The endothelial cells were then cultured in medium 
composed of human endothelial basal growth medium (Life technologies), 10% AB human 
serum (HD supplies), 10ng/ml vascular endothelial growth factor (VEGF), and 10ng/ml 
hepatocyte growth factor (HGF) (Peprotech). The cells were grown in collagen-coated 
culture flasks and were maintained at 37°C in a humidified incubator with 5% CO2 until 
confluent.
Isolation of peripheral blood lymphocytes (PBLs)
PBLs were isolated as previously described61 by density gradient centrifugation over 
Lympholyte (VH Bio) at 800xg for 25 minutes. Harvested Lymphocytes were re-suspended 
in RPMI 1640 (Life Technologies) /10% fetal calf serum.
Flow adhesion assay
To study immune cell recruitment, HSEC were grown in Ibidi μ-slide IV flow channels 
(Thistle scientific, Glasgow UK) until confluent. HSEC were then cultured in conditioned 
media for 24 hours prior to connection to the flow system previously described35. Peripheral 
blood lymphocytes were perfused through the microslides over the endothelial cells at a 
shear stress of 0.05Pa. Phase contrast video recordings made during lymphocyte perfusion 
were analysed offline to determine adherence.
Analysis of the IL1A locus
All sequence data was obtained from IMR90 cells. IL1A is shown with both the hg19 
RefSeq annotation62, and GenCode version 19 annotation63. C/EBPβ ChIP-Seq and 
DNAase-Seq data are from the Encode Project39, and Histone data is from the Roadmap 
Epigenomics Project40. The data was visualised using the Gviz Bioconductor library.
Chromatin immunoprecipitation (ChIP)
ChIP was performed as described previously64 with modifications. Briefly, 50ug of 
chromatin and 10ug of antibody (C/EBPβ: Santa Cruz sc-150) were applied to each IP. For 
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the negative control no antibody was added to the IP. Three replicate ChIPs were carried out 
for each condition followed by qPCR. Primer sequences used in qPCR are as follows:
IL6 (-176/-122) F (target)*: GCCATGCTAAAGGACGTCACA
IL6 (-176/-122) R (target)*: GGGCTGATTGGAAACCTTATTAAGA
IL6 (-1158/-1094) F (non-specific)*: CCATCCTGAGGGAAGAGGG
IL6 (-1158/-1094) R (non-specific)*: CGTCGGCACCCAAGAATTT
IL8 (-134/-45) F (target)*: AAGTGTGATGACTCAGGTTTGC
IL8 (-134/-45) R (target)*: GCACCCTCATCTTTTCATTATG
IL8 (-1324/-1240) F (non-specific)*: TCACTGCTCTGTCGTACTTTCTG
IL8 (-1324/-1240) R (non-specific)*: CGCTTCTGGGCAAGTACATA
IL1A proximal F (target): CTGGCAGCTTAAGCCTGAGT
IL1A proximal R (target): TAAATTCCCCGTTTTGACGA
IL1A distal F (target): GGCCAGAGAACTGTGAGAGG
IL1A distal R (target): TGCATCAGGGCAAGTTTATG
IL1A non-specific F (non-specific): AGGGGCTAGATTTGGAGAGG
IL1A non-specific R (non-specific): ATTCACCCTGGAGCACAATC
* The primer sets for IL6 and IL8 were previously reported6. For IL1A ‘Proximal’ 
(promoter) and ‘Distal’ (enhancer), qPCR primers were designed based on C/EBPβ ChIP-
seq data (ENCODE). In this case, ‘non-specific’ is upstream of the IL1A promoter. The 
locations of the primer sets for IL1A are illustrated in Supplemental Figure 8E.
Statistics and reproducibility
No statistical method was used to predetermine sample size. The experiments were not 
randomised and the investigators were not blinded to allocation during experiments. Unless 
otherwise stated, data are represented by the mean ± SEM. n values represent the number of 
independent experiments performed or the number of individual mice per condition. For 
each independent in vitro experiment a minimum number of three experiments were 
performed to ensure reproducibility and adequate statistical power. For in vivo experiments 
all conclusions were based on a minimum of 3 mice per condition or time point. Analyses 
were conducted using Graphpad Prism 6. Student’s t-test was used for two-condition 
comparisons; one-way ANOVA with Dunnett’s multiple comparison test for more than 2 
conditions. In the statistical analyses two-tailed tests were used throughout; a p-value of 0.05 
was taken as significant. All the study data including statistical tests and exact p-values is 
provided in supplementary table 2.
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Data availability
The RNA-Sequencing data generated for this study have been deposited at the Gene 
expression omnibus (GEO) with the accession numbers: GSE72404, GSE72407 and 
GSE72409. The mass spectrometry proteomics data have been deposited to the 
ProteomeXchange Consortium via the PRIDE 82 partner repository with the dataset 
identifier PXD004168. (http://proteomecentral.proteomexchange.org).
The TGFB1 signature was derived from previously published data available from GEO 
under accession codes GSE1249365 and GSE2966066. The CEBPB signature was derived 
from previously published data available from GEO under accession codes GSE47777 and 
GSE3083437. Chromatin immunoprecipitation datasets were obtained from GEO with the 
following accessions: CEBPB, GEO ID: GSM935519; DNase-Seq, GEO ID: GSM1008586; 
H3K27ac, GEO ID: GSM469966; H3K4me1, GEO ID: GSM521895; H3K4me3, GEO ID: 
GSM521901.
Proteomics data from Fig. 1 and Supplementary Fig. 1 have been provided as Supplementary 
Table 1. Source data for Figures 2 - 8 and Supplementary Figures 1, 2, 4, 5, 6 and 8 have 
been provided as Supplementary Table 2. All other data supporting the findings of this study 
are available from the corresponding author on reasonable request.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Plasma membrane proteomics (PMP) defines NOTCH1 as upregulated in OIS.
(a) The workflow for quantitative PMP using differential SILAC labelling of growing and 
HRASG12V-induced senescent (RIS) IMR90 cells. (b) GO cellular compartment term 
enrichment for all 1502 identified proteins in both conditions. (c) Volcano plot of 521 high-
confidence protein identifications from PMP demonstrating log2 fold change (RIS(d6) / 
Growing) against negative log10 p value (n = 4 independent experiments). Among 167 
proteins differentially expressed during RIS (p<0.05), red dots indicate 94 proteins with 
more than two fold change. (d) Cell surface NOTCH1 expression by flow-cytometry in 
indicated IMR90 cells: left, ER:HRASG12V cells with (d6) or without (Growing) 4OHT, iso-
IgG, isotype control IgG; centre, cells with constitutive overexpression of either HRASG12V, 
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E1A, or both; right, DNA damage-induced senescence (DDIS). To establish DDIS, cells 
were treated with 100μM Etoposide for 2 days, followed by 5-days incubation in drug-free 
medium.
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Figure 2. Dynamic canonical NOTCH1 signalling is responsible for reciprocal regulation of TGF-
β ligands and pro-inflammatory cytokines during senescence.
(a) Time series analysis of cell surface NOTCH1 expression during RIS in IMR90 cells by 
flow cytometry. Values are means relative to d0 ± SEM from 3 independent experiments. (b 
and c) Time course of protein expression by immunoblotting during RIS (b) or DDIS (c). (d) 
ER:HRASG12V IMR90 cells, expressing dnMAML1-mVenus or matched control, were 
incubated with or without 4OHT for 3 days and analysed for expression of indicated mRNA 
and proteins by qRT-PCR and immunoblotting respectively; n = 5 biologically independent 
experiments for TGFB1 and IL1B, n = 4 biologically independent experiments for IL1A; 
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unpaired T-test. (e) ER:HRASG12V IMR90 cells, expressing a doxycycline-inducible 
N1ICD-FLAG construct (TRE-N1ICD) were analysed after 6 days treatment with 4OHT 
with or without doxycycline at indicated concentrations from d3 by qRT-PCR and 
immunoblotting; n = 6 biologically independent experiments for all conditions (except 
4OHT / 1 μM Doxy where n = 5); unpaired T-test. Values are mean ± SEM; *P ≤ 0.05, **P 
≤ 0.01, ***P ≤ 0.001. Statistics source data for a, d & e are provided in Supplementary Table 
2.
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Figure 3. NOTCH1 drives a cell-autonomous senescence with a distinct secretory profile.
(a and b) ER:HRASG12V IMR90 cells, stably expressing N1ICD-FLAG or control vector 
(V), were incubated with or without 4OHT for 6 days and analysed for expression of 
indicated proteins by immunoblotting (a), SA-β-gal and BrdU incorporation (b). One way 
ANOVA with Dunnett's multiple comparison test; bars are means of ≥200 cells, n = 4 
biologically independent experiments. ***P ≤ 0.001 versus control cells. Scale bar 100μm. 
(c) Time series analysis of indicated transcripts after doxycycline (Doxy) induction in TRE-
N1ICD-FLAG IMR90 cells by qRT-PCR. Values are mean ± SEM, n = 3 biologically 
Hoare et al. Page 27
Nat Cell Biol. Author manuscript; available in PMC 2017 March 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
independent experiments. Inset, immunoblotting of fractionated chromatin in IMR90 cells 
expressing HRASG12V (d6) or TRE-N1ICD-FLAG (d3) for downstream TGF-β 
phosphorylation-target SMAD3 (phos-SMAD3). (d) TRE-N1ICD-mVenus IMR90 cells with 
or without 3 days of doxycycline were analysed for cell surface expression of the TGFB1 
gene product latency-associated peptide by flow cytometry. (e) Differentially expressed 
transcripts in N1ICD-, HRASG12V- or Etoposide-induced senescent IMR90 cells (NIS, RIS, 
or DDIS, respectively), compared to normal control cells. Heat map shows z-score 
normalised fold changes of 1150 secretome genes differentially expressed in at least in one 
comparison. Representative KEGG pathways enriched in four clusters (False discovery rate 
(FDR) < 0.01) are shown. (f) TRE-N1ICD-FLAG IMR90 cells treated with or without 
doxycycline for 3 days with or without TGF-β receptor antagonists (#1, SB431542; #2, 
A83-01) were analysed by qRT-PCR and immunoblotting for the indicated mRNA and 
proteins in addition to proliferation and cell cycle analyses. Values are mean ± SEM, n = 5 
biologically independent experiments for CDKN2B; n = 4 biologically independent 
experiments for TGFBI. Statistics source data for b, c & f are provided in Supplementary 
Table 2.
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Figure 4. NOTCH1 drives non-cell-autonomous senescence partly dependent upon TGF-β.
(a) The proliferative ability of mRFP cells was analysed during co-culture with unlabelled 
senescent cells by proliferation analysis; representative images demonstrating co-cultured 
cells. Scale bar 150 μm. NIS, doxycycline was added at d0 to induce N1ICD; RIS, 
ER:HRASG12V was pre-induced for 4 days before co-culture; DDIS, senescence was 
induced by etoposide as in Figure 2C for 4 days before co-culture. (b) mRFP cells were co-
cultured with doxycycline-inducible TRE-N1ICD cells treated with or without doxycycline 
for 3 days prior to flow sorting and expression analysis of the 2 cell populations for the 
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indicated transcripts by qRT-PCR; unpaired T-test; bars are means, n = 3 independent 
biological replicates. (c) The proliferative ability of mRFP IMR90 cells was analysed during 
co-culture with TRE-N1ICD IMR90 cells treated with or without doxycycline and TGF-β 
receptor antagonists; representative result from 5 biologically independent experiments with 
similar results. (d and e) mRFP (puromycin-resistant) cells were co-cultured with cells 
stably expressing N1ICD-FLAG (hygromycin-resistant) for 7 days prior to puromycin 
selection to selectively remove N1ICD-expressing cells, yielding populations that were 
~99% mRFP-positive by flow cytometry. mRFP cells were then analysed for expression of 
indicated proteins by immunoblotting (d), SA-β-gal and DNA synthesis by BrdU 
incorporation (e); unpaired T-test; values are mean ± SEM of ≥200 cells from 8 high power 
fields, n = 7 biologically independent experiments. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. 
Scale bar 200 μm. Statistics source data for b & e are provided in Supplementary Table 2.
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Figure 5. NOTCH1 drives juxtacrine senescence through JAG1-mediated lateral induction in 
IMR90 cells.
(a) Time series analysis of JAG1 expression by immunoblotting (upper) and at the cell 
surface by flow cytometry (lower) after doxycycline induction in TRE-N1ICD cells. (b) The 
proliferative ability of mRFP cells was analysed during co-culture with TRE-N1ICD cells 
treated with or without doxycycline and the gamma secretase inhibitor DAPT at indicated 
concentrations; representative result from 4 biologically independent experiments with 
similar results. (c) The proliferative ability of TRE-N1ICD cells was analysed with or 
without doxycycline and DAPT at indicated concentrations; representative result from 4 
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biologically independent experiments with similar results. (d) The proliferative ability of 
mRFP cells with stable expression of dnMAML1-mVenus or mVenus alone was analysed 
during co-culture with TRE-N1ICD cells treated with or without doxycycline; representative 
result from 4 biologically independent experiments with similar results. (e and f) Expression 
of JAG1 and proliferation of TRE-N1ICD cells stably expressing vector or indicated 
shRNAs targeting JAG1, demonstrated by immunoblot (e) and proliferation analysis with or 
without doxycycline (f); representative result from 4 biologically independent experiments 
with similar results. (g) The proliferative ability of mRFP cells was analysed during co-
culture with TRE-N1ICD cells with or without sh-JAG1 and with or without doxycycline. 
(h) mRFP cells were analysed for BrdU incorporation, when physically separated from 
TRE-N1ICD cells treated with or without doxycycline in a transwell chamber; unpaired T-
test; ≥200 cells from 8 high power fields; n = 5 independent biological replicates. (i) TRE-
N1ICD cells treated with or without doxycycline and TGF-β receptor antagonists (left) or 
co-transfected with vector or dnSMAD4 (right) were analysed for JAG1 expression by qRT-
PCR; n = 3 biologically independent experiments; 1, SB431542; 2, A83-01. One way 
ANOVA with Dunnett's multiple comparison test (left) or unpaired t-test (right); bars are 
means (h and i) ± SEM (h). Statistics source data for h & i are provided in Supplementary 
Table 2.
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Figure 6. NOTCH1 is dynamically upregulated within NRAS-senescent hepatocytes and inhibits 
senescence surveillance.
(a) Livers were harvested from mice 12 days after hydrodynamic tail vein injection of 
NRASG12V or inactive NRASG12V/D38A-bearing transposons and analysed by 
immunohistochemistry for NRAS and Notch1 expression in serial sections; Quantification 
of NRAS+ hepatocytes expressing NOTCH1; values are mean ± SEM from manual counting 
of ≥200 cells; n = 3 mice per condition. Insets, magnified pictures of dotted rectangular 
areas. Scale bar 200 μm. (b) Time series analysis of hepatic NRAS-expression by 
immunohistochemistry after injection of NRASG12V(-IRES-mVenus) or NRASG12V-IRES-
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dnMAML1(-mVenus). Scale bar 200 μm. (c) Quantification of NRAS, p21, or CD3 (T-
lymphocyte marker) positive cells within livers of mice treated as in (b); unpaired T-test; 
values are mean ± SEM from manual counting (NRAS) or automated image analysis of 
≥105 cells (p21 / CD3) from liver sections (see METHODS); for NRASG12V injected 
animals at D6, 9 & 12, n = 3, 3 & 4 mice respectively; for NRASG12V-IRES-dnMAML1 
injected animals at D6, 9 & 12, n = 4, 3 & 5 mice respectively; *P ≤ 0.05, **P ≤ 0.01. (d) 
Lateral induction of Notch signalling in mouse livers treated as in (b). Representative 
immunohistochemistry of NRAS and Hes1 at d9 in serial sections. Insets, magnified pictures 
of dotted rectangle areas. Asterisk demonstrates Hes1-expressing, NRAS-negative cells 
adjacent to NRAS-expressing hepatocytes. Arrowheads demonstrate positive internal control 
staining of Hes1 within cholangiocytes. The percentage of NRAS-positive cells with 
adjacent Hes1-positive (but not NRAS) were manually counted; n = 3 mice per condition; 
bars are means; unpaired T-test. Similar results were also obtained using dual staining in the 
same section (Supplemental Fig. 6C). Scale bar 200 μm. (e) Flow-based assay of peripheral 
blood lymphocyte (PBL) adherence (cells/mm2/106) to human liver sinusoidal endothelial 
cells (HSEC) from 3 separate individuals pre-incubated with conditioned media (CM) from 
IMR90 cells expressing ER:HRASG12V and TRE-N1ICD with or without 4OHT (d6) 
and/or doxycycline (d3) (left; n = 3 biologically independent replicates or CM from 
ER:HRASG12V IMR90 cells, expressing dnMAML1-mVenus or matched control and 
incubated with or without 4OHT for 3 days (right; n = 3 biologically independent replicates) 
(see Supplementary Fig. 7A, B). Representative images (bottom) demonstrating adherent 
PBLs (arrows) to HSEC after pre-incubation with indicated CM. One way ANOVA with 
Dunnett's multiple comparison test; bars are mean; *P ≤ 0.05, **P ≤ 0.01. Scale bar 50μm. 
Statistics source data for a, c, d & e are provided in Supplementary Table 2.
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Figure 7. Co-expression of NRASG12V and N1ICD drives short-term apoptosis and long-term 
tumourigenesis in the liver.
(a-c) Livers from mice injected with either NRASG12V or NRASG12V-IRES-N1ICD were 
subjected to IHC for NRAS and cleaved caspase 3 staining at the indicated time points in 
serial sections. Relatively fewer NRAS-positive hepatocytes were detected in the 
NRASG12V-IRES-N1ICD cohort (a), and these NRAS-positive cells were mostly positive 
for cleaved caspase 3 (d6) (b, c). Insets are magnified pictures of dotted rectangular areas 
(b). Bars are means from automated image analysis of ≥105 cells from each liver section; D6 
NRASG12V n = 4 mice, D12 NRASG12V n = 6 mice, D6 NRASG12V-IRES-N1ICD n = 4 
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mice, D12 NRASG12V-IRES-N1ICD n = 7 mice; unpaired t-test. Scale bar 200 μm. (d) Mice 
injected with NRASG12V (n = 7 mice) or NRASG12V-IRES-N1ICD (n = 9 mice) underwent 
long-term follow-up; necropsy was performed in all to confirm the presence of liver 
tumours. Kaplan-Meier plots of cancer-free survival from the 2 cohorts; survival analysis by 
Log-rank test. (e) Example images of gross liver pathology at 2 months post-HDTV 
injection of one mouse from each cohort revealing a large tumour (long black arrow) and 
multiple small cystic lesions in the liver injected with NRASG12V-IRES-N1ICD. (f - g) 
Immunohistochemical and H&E staining of serial liver sections from each cohort for the 
indicated proteins. H&E staining demonstrating tumour (T) infiltrating the surrounding 
normal parenchyma (N) and strong tumoural immunohistochemical staining for the 
proliferative marker ki67 in serial sections (g). Images in (g) are magnified views of dotted 
rectangular areas in (f). *P ≤ 0.05, **P ≤ 0.01. Scale bar upper panels 5mm, lower panels 
200 μm. Statistics source data for a & c are provided in Supplementary Table 2.
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Figure 8. NOTCH1 controls the pro-inflammatory SASP through repression of C/EBPβ.
(a) ER:HRASG12V/TRE-N1ICD-FLAG IMR90 cells treated with or without 6 days of 
4OHT and 3 days of doxycycline were analysed for expression of RELA and C/EBPβ in 
whole cell lysate and fractionated chromatin by immunoblotting. (b) Time series analysis of 
chromatin-bound N1ICD-FLAG and C/EBPβ after doxycycline treatment of TRE-N1ICD 
IMR90 cells with or without dnMAML1. (c and d) TRE-N1ICD IMR90 cells with or 
without ectopic C/EBPβ-LAP* and 3 days of doxycycline treatment were analysed for C/
EBPβ, IL-8 (c) and IL1A (d) expression by immunoblot and qRT-PCR; n = 3 biologically 
independent experiments. (e) TRE-N1ICD IMR90 cells treated with or without doxycycline 
for 3 days, then with or without 100ng/ml TNF-α for 1 hour were analysed for expression 
and chromatin binding of indicated mRNA and proteins by qRT-PCR and immunoblot 
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respectively; unpaired T-test; n = 3 biologically independent experiments; bars are means. (f) 
TRE-N1ICD IMR90 cells treated with or without doxycycline for 3 days, and 10ng/ml 
IL-1α for the final 24 hours were analysed by immunoblotting. (g) ER:HRASG12V- and 
TRE-N1ICD-FLAG-expressing IMR90 cells treated with or without 6 days of 4OHT and 3 
days of doxycycline were subjected to chromatin immunoprecipitation of endogenous C/
EBPβ and subsequent qPCR for proximal and distal sites at the IL1A locus (Supplemental 
Figure 8E and METHODS); n = 3 biologically independent experiments; One way ANOVA 
with Dunnett's multiple comparison test; values are mean ± SEM. (h) Model for NOTCH-
mediated SASP switch during senescence. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. Statistics 
source data for d, e & g are provided in Supplementary Table 2.
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